



Open Government Impact Statement

82nd Oregon Legislative Assembly
2023 Regular Session

Measure: HB 2617 - A

Only impacts on Original or Engrossed
Versions are Considered Official

Prepared by: Cameron D. Miles
Date: 3/14/2023

SUMMARY

Directs Oregon Health Authority, in consultation with Newborn Bloodspot Screening Advisory Board, to adopt rules for board to evaluate and recommend adding disease to or removing disease from newborn bloodspot screening panel or taking no action on disease. Requires board to evaluate and make recommendations pursuant to rules, including rules for public request process. Requires board to meet at least four times per calendar year and to submit biennial report to Legislative Assembly. Shortens term of office of board member to two years. Limits reappointment. Modifies board membership and requirements. Subjects board meetings to public meetings law. Waives newborn bloodspot screening fees for parents or guardians who pay out of pocket birthing fees as defined by rule by authority or who are indigent or otherwise unable to pay newborn bloodspot screening fees.

Requires authority to consider, and to greatest extent practicable implement, screening for disease no later than 18 months after federal committee recommends adding disease to federal Recommended Uniform Screening Panel. Directs authority to complete pilot study to demonstrate standards, criteria and processes for determining whether to add disease to newborn bloodspot screening panel and to report to Legislative Assembly on findings and recommendations for improvements.

Declares emergency, effective on passage.

NOTICE OF NO OPEN GOVERNMENT IMPACT